Daewoong finishes resubmitting documents for Nabota to FDA

Daewoong Pharmaceutical’s botulinum toxin ‘Nabota’ has taken the last step to enter the U.S. market.

Daewoong Pharmaceutical(CEO Seung-Ho Jeon) announced on the 2^nd that they turned in revised documents to the U.S. FDA and resumed the application process for Nabota’s sales approval in the U.S. This is a follow-up action to the Complete Response Letter(CRL) from the FDA last May; the FDA reques...